Gilead Awards $7.6 Million in Grants to Advance Health Equity in Breast Cancer - Seite 2

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, inflammation and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Gilead has promoted equity, particularly healthcare equity, since the company brought its first therapies to the market. Through global partnerships, Gilead’s medicines today reach millions of people in low- and middle-income countries around the world. In the United States, Gilead has committed more than $100 million over 10 years through the COMPASS Initiative to community organizations that are working to combat HIV in the U.S. South. In 2020, Gilead launched the Racial Equity Community Impact Fund to support organizations tackling racial inequities affecting Black communities across the United States.

Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.
For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

¹ Breast Cancer Statistics. The American Society of Clinical Oncology. Breast Cancer: Statistics | Cancer.Net. Last accessed January 31, 2023.
² Cancer Disparities. The National Cancer Institute. Cancer Disparities - NCI. Last accessed January 31, 2023.
³ Key Statistics for Breast Cancer. The American Cancer Society. https://www.cancer.org/cancer/breast-cancer/about/how-common-is-breast ..., last accessed January 31, 2023.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230131006146/en/

The Gilead Sciences Stock at the time of publication of the news with a fall of -0,12 % to 76,72EUR on Tradegate stock exchange (01. Februar 2023, 14:12 Uhr).